12,450
-0.80%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Kolon Life Science
Its shares trade on KOSDAQ under the ticker 102940.KQ. It has been listed since 7 April 2009. In the fiscal year to 31 December 2025, it reported revenue of ₩208.98bn and net income of ₩24.96bn. At that date it held total assets of ₩914.41bn and shareholders' equity of ₩584.03bn.
KOLON Life Science, Inc. engages in the manufacture and sale of pharmaceuticals and environment materials. The company is headquartered in Seoul, Seoul. The company went IPO on 2009-04-07. The firm operates its business under two segments. The Chemical Business segment produces and sells raw drug products, which are the raw materials of new drugs and generic drugs, antibacterial agents that suppress bacterial growth, water treatment agents for environmental purification, and functional material products for cosmetics. The Bio Business segment manufactures and sells bio new medicines based on cell gene therapy products.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 7 Apr 2009
- Employees
- 432
- Website
- kolonls.co.kr ↗
Leadership
Pay as last reported
- Seon Jin KimChief Executive Officer, Director, since 2023
- Myeong Gwan SeoManaging Director, since 2012
- Tae Geun ChoiAssistant Managing Director
- Beom Seop LeeAssistant Managing Director
- Sang Wu LeeAssistant Managing Director
- Seok Jun LeeAssistant Managing Director
- Sang Hu ParkAssistant Managing Director
- Dae Gyo SeoInternal Auditor
- Mr. Wung Yeol LeeDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Kolon Life Science Inc. manufactures raw drug products for new and generic drugs in Seoul.
- The Chemical Business segment produces antibacterial agents and water treatment agents for environmental purification.
- The Bio Business segment focuses on cell gene therapy products for bio new medicines.
Weaknesses
- Kolon Life Science Inc. operates only in the Health Care sector with no diversification.
- The company has a small employee count of 432 full-time staff in Seoul.
- The firm's business is limited to two segments without expansion into other industries.
Opportunities
- The Bio Business segment can expand into cell gene therapy markets in South Korea.
- The Chemical Business segment can increase sales of water treatment agents for environmental purification.
- Kolon Life Science Inc. can leverage its Seoul headquarters for regional market growth.
Threats
- The Health Care sector faces regulatory challenges in South Korea.
- Competition in the pharmaceutical industry may impact Kolon Life Science Inc.'s market share.
- The company's reliance on two business segments poses a risk if one segment underperforms.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.